PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19727679-0 2009 Further evidence of association between amphetamine response and SLC6A2 gene variants. Amphetamine 40-51 solute carrier family 6 member 2 Homo sapiens 66-72 21149640-1 2011 The human dopamine and norepinephrine transporters (hDAT and hNET, respectively) control neurotransmitter levels within the synaptic cleft and are the site of action for amphetamine (AMPH) and cocaine. Amphetamine 170-181 solute carrier family 6 member 2 Homo sapiens 61-65 21149640-1 2011 The human dopamine and norepinephrine transporters (hDAT and hNET, respectively) control neurotransmitter levels within the synaptic cleft and are the site of action for amphetamine (AMPH) and cocaine. Amphetamine 183-187 solute carrier family 6 member 2 Homo sapiens 61-65 20626559-0 2010 Involvement of threonine 258 and serine 259 motif in amphetamine-induced norepinephrine transporter endocytosis. Amphetamine 53-64 solute carrier family 6 member 2 Homo sapiens 73-99 29428394-5 2018 Amphetamine actions include dopamine and norepinephrine transporter inhibition, vesicular monoamine transporter 2 (VMAT-2) inhibition, and monoamine oxidase activity inhibition. Amphetamine 0-11 solute carrier family 6 member 2 Homo sapiens 41-67 20534835-0 2010 Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking. Amphetamine 15-26 solute carrier family 6 member 2 Homo sapiens 38-64 16515684-10 2006 The order of amphetamine potencies was NET (KI = 0.07-0.1 microM), DAT (KI approximately 0.6 microM), and SERT (KI between 20 to 40 microM). Amphetamine 13-24 solute carrier family 6 member 2 Homo sapiens 39-42 17032905-0 2007 Amphetamine induces a calcium/calmodulin-dependent protein kinase II-dependent reduction in norepinephrine transporter surface expression linked to changes in syntaxin 1A/transporter complexes. Amphetamine 0-11 solute carrier family 6 member 2 Homo sapiens 92-118 17032905-6 2007 In hNET-CAD cells, AMPH causes a slow and small reduction of surface hNET with a modest increase in hNET/SYN1A associations at the plasma membrane. Amphetamine 19-23 solute carrier family 6 member 2 Homo sapiens 3-7 17032905-6 2007 In hNET-CAD cells, AMPH causes a slow and small reduction of surface hNET with a modest increase in hNET/SYN1A associations at the plasma membrane. Amphetamine 19-23 solute carrier family 6 member 2 Homo sapiens 69-73 17032905-6 2007 In hNET-CAD cells, AMPH causes a slow and small reduction of surface hNET with a modest increase in hNET/SYN1A associations at the plasma membrane. Amphetamine 19-23 solute carrier family 6 member 2 Homo sapiens 69-73 17239355-2 2007 Because the effects of amphetamine are mediated in part by the norepinephrine transporter (SLC6A2), we examined interindividual differences in mood response to amphetamine in relation to SLC6A2 gene polymorphisms. Amphetamine 160-171 solute carrier family 6 member 2 Homo sapiens 91-97 15757904-2 2005 In spite of its central importance in the nervous system, little is known about how NET substrates, such as NE, 1-methyl-4-tetrahydropyridinium (MPP+), or amphetamine, interact with NET at the molecular level. Amphetamine 155-166 solute carrier family 6 member 2 Homo sapiens 182-185 16289633-1 2006 The norepinephrine (NE) transporter (NET) mediates the removal of NE from synaptic spaces and is a major target for antidepressants, amphetamine and cocaine. Amphetamine 133-144 solute carrier family 6 member 2 Homo sapiens 37-40 11082428-0 2000 Regulation of the human norepinephrine transporter by cocaine and amphetamine. Amphetamine 66-77 solute carrier family 6 member 2 Homo sapiens 24-50 11082428-7 2000 In contrast, incubation of cells with amphetamine significantly reduced [(3)H]nisoxetine binding to NET and levels of NET immunoreactivity in a time-dependent manner, although levels of NET mRNA appeared to be unaffected. Amphetamine 38-49 solute carrier family 6 member 2 Homo sapiens 100-103 11082428-7 2000 In contrast, incubation of cells with amphetamine significantly reduced [(3)H]nisoxetine binding to NET and levels of NET immunoreactivity in a time-dependent manner, although levels of NET mRNA appeared to be unaffected. Amphetamine 38-49 solute carrier family 6 member 2 Homo sapiens 118-121 11082428-7 2000 In contrast, incubation of cells with amphetamine significantly reduced [(3)H]nisoxetine binding to NET and levels of NET immunoreactivity in a time-dependent manner, although levels of NET mRNA appeared to be unaffected. Amphetamine 38-49 solute carrier family 6 member 2 Homo sapiens 118-121 11082428-10 2000 Cocaine and amphetamine have distinctly different effects on NET expression after continuous exposure. Amphetamine 12-23 solute carrier family 6 member 2 Homo sapiens 61-64 9030630-1 1997 The norepinephrine transporter (NET) is a site of action for tricyclic antidepressant drugs and for drugs of abuse such as amphetamine and cocaine. Amphetamine 123-134 solute carrier family 6 member 2 Homo sapiens 4-30 10531412-6 1999 In the presence of low chloride (DAT: 3 mM; NET: 2 mM), however, amphetamine as well as the catecholamines stimulated release from both types of cell. Amphetamine 65-76 solute carrier family 6 member 2 Homo sapiens 44-47 9030630-1 1997 The norepinephrine transporter (NET) is a site of action for tricyclic antidepressant drugs and for drugs of abuse such as amphetamine and cocaine. Amphetamine 123-134 solute carrier family 6 member 2 Homo sapiens 32-35 8610762-12 1995 CONCLUSIONS: The results show that the norepinephrine transporter and, to a lesser extent, the serotonin transporter are cellular targets in the human placenta for the abusable drugs amphetamine and methamphetamine. Amphetamine 183-194 solute carrier family 6 member 2 Homo sapiens 39-65